In vivo evaluation of anticryptosporidiosis activity of the methanolic extract of the plant Umbilicus rupestris

##plugins.themes.bootstrap3.article.main##

AFAF BENHOUDA
DJAHIDA BENHOUDA
MASSINISSA YAHIA

Abstract

Abstract. Benhouda A, Benhouda D, Yahia M. 2019. In vivo evaluation of anticryptosporidiosis activity of the methanolic extract of the plant Umbilicus rupestris. Biodiversitas 20: 3478-3483. Umbilicus rupestris (Crassulaceae) is a medicinal plant used in general traditional medicine to cure inflammation and irritation of the skin. The present research is aimed to evaluate the antiparasitic activity of the methanolic extract of the plant URMeOH of U. rupestris against the Cryptosporidium infection in immunocompetent and immunosuppressed rats experimentally infected. Twenty-one female rats were divided into two groups. Control group (group I) and experimental group (Group II). The group I was further divided into three equal groups (normal group infected and immunosuppressed infected group). The experimental group was divided into two immunosuppressed and four equal groups and two immunocompetent infected. Cryptosporidium oocysts were isolated from bovine species stools and used to infect rats. Experimental subgroups received URMeOH two as dose 100mg/kg b.w. and 200 mg/kg b.w. and continued until 15 days. Two weeks after the administration of URMeOH, feces of rats were examined for the detection of Cryptosporidium oocysts by Ziehl-Neelsen and immunofluorescence techniques, the animals were sacrificed; their small intestines were processed and examined for the detection of pathological lesions after histopathological study. In addition, the activity of myeloperoxidase (MPO) was measured in sections of the jejunum. Concerned the results, we observed a statistically significant (P<0.001) increase in the number of oocysts of Cryptosporidium in the stool for sub infected immunosuppressed groups and an increase of MPO activity compared to the corresponding subgroups immunocompetent subgroups. The URMeOH could remove Cryptosporidium oocysts from feces and intestinal sections subgroup infected immunocompetent rats receiving URMeOH. Moreover, the oocysts were significantly reduced in all other subgroups experimental infected compared to infected control subgroups. Intestinal sections in all subgroups received URMeOH revealed a more or less normal architecture. In addition, the reduction of MPO activity level was also detected in all experimental subgroups.

##plugins.themes.bootstrap3.article.details##

References
Atanasov AG, Waltenberger B, Pferschy-WenzigEM., Linder T.2015. Discovery and resupply of pharmacologically active plant-derived natural products: A review.Biotechnol Adv 33(8): 1582–1614.

Babior BM.2000. Phagocytes and oxidative stress . American Journal of Medicine 109 (1) : 33-44.
Bouzid M, Hunter PR, Chalmers RM, and Tyler KM .2013.Cryptosporidium Pathogenicity and Virulence. Clin Microbiol Rev 26(1): 115–134.

Camenga D. LNathanson N. Cole G. A. 1974. Cyclophosphamide-potentiated West Nile viral encephalitis: relative influence of cellular and humoral factors. J. Inf. Dis.130 :634-641.

Casemore D P. 1991.Laboratory methods for diagnosing cryptosporidiosis. J Clin Pathol;44(6): 445–451.
Di Genova BM and Tonelli RR.2016. Infection Strategies of Intestinal Parasite Pathogens and Host Cell Responses. Front. Microbiol 7 :1-16.

Farthing MJ.2000. Clinical aspects of human cryptosporidiosis. Contrib. Microbiol 6:50–74.
Fayer R, Morgan U, Upton SJ.2000. Epidemiology of Cryptosporidium: Transmission, detection and identification International Journal for Parasitology 30(12-13):1305-1322.
Gaafar MR.2007. Effect of solar disinfection on viability of intestinal protozoa in drinking water. J Egypt Soc Parasitol;37(1):65-86.
Karlsson A, Dahlgren C.2002. Assembly and activation of the neutrophil NADPH oxidase in granule membranes. Antioxid. Redox Signal 4 : 49-60.
Khan AA, Rahmani AH, Aldebasi YH, Aly SH.2014. Biochemical and pathological studies on peroxidases –An updated review. Glob. J. Health Sci. ;6:87–98.
Khan AA. , Alsahli MA., and Rahmani AH.2018. Myeloperoxidase as an Active Disease Biomarker: Recent Biochemical and Pathological Perspectives . Med Sci (Basel) 6(2): 33.

Klebanoff SJ.1999.Myeloperoxidase. Proceedings of the Association of American Physicians 111 :383-389.

Klebanoff SJ. 2005. Myeloperoxidase: Friend and foe Journal of Leukocyte Biology 77 (5) : 598-625.

Leitch GJ and He Q.2001. Cryptosporidiosis-an overview. J Biomed Res25(1): 1–16.
Liu WQ., Zhang YZ, Wu Y, Zhang JJ, Li TB, Jiang T, Xiong XM, Luo XJ, Ma QL, Peng J.2015. Myeloperoxidase-derived hypochlorous acid promotes ox-LDL induced senescence of endothelial cells through a mechanism involving ?-catenin signaling in hyperlipidemia. Biochem. Biophys. Res. Commun 467:859–865.
Lumb R,Lanser JA,O’Donoghue PJ.1998. Electrophoretic and immunoblot analysis of Cryptosporidium oocysts. Immunol.Cell.Biol 66 :369-370.
Nicholls SJ, Hazen SL. 2005. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol 25:1102–1111.
Serteyn D,Grulke S, franck T.2003. La myéloperoxydase des neutrophiles, une enzyme de défense aux capacités oxydantes. Ann. Méd. Vét.147, 79-93.
Sparks H, Nair G., MD, Castellanos-Gonzalez A.2015. Treatment of Cryptosporidium: What We Know, Gaps, and the Way ForwardCurr Trop Med Rep.2(3): 181–187.

Sponseller JK, Griffiths JK, Tzipori S.2014. The Evolution of Respiratory Cryptosporidiosis: Evidence for Transmission by Inhalation .Clin Microbiol Rev.; 27(3): 575–586.
Williams JE. 1998. Diagnostic medical parasitology. Parasitol Today. 14(3):125-6.
Yamaguchi R, Kawata J, Yamamoto T, Ishimaru Y, Sakamoto A, Ono T, Narahara S, Sugiuchi H, Hirose E, Yamaguchi YY.2015. Mechanism of interferon-? production by monocytes stimulated with myeloperoxidase and neutrophil extracellular traps. Blood Cells Mol. Dis ;55:127–133.